Recombinant Antitrypsin Pittsburgh Undergoes Proteolytic Cleavage during E. coli Sepsis and Fails to Prevent the Associated Coagulopathy in a Primate Model

Summary

During severe sepsis there is dramatic activation of both contact pro-teases and the coagulation pathway. These processes contribute to the development of shock and disseminated intravascular coagulation (DIC) respectively. The Pittsburgh mutant of antitrypsin (358Met-Arg) is a novel protease inhibitor with activity against both thrombin and the contact proteases and should therefore prove beneficial as a therapeutic agent in the management of septic shock. This hypothesis was supported by an earlier study in a pig model where recombinant antitrypsin Pittsburgh (rAT Pittsburgh) at a concentration of 1 μM alleviated some of the features of shock, but did not improve survival. In order to reduce the lethal effects of E. coli sepsis we postulated that a higher concentration of antitrypsin Pittsburgh would be necessary. To test this hypothesis we used rAT Pittsburgh in a primate model. This was chosen in preference to another species as E. coli sepsis in the primate has been well characterised and closely resembles the changes seen in man.

Surprisingly this treatment did not alleviate the features of shock and unexpectedly appeared to exacerbate the associated coagulopathy. We propose two possible mechanisms for this unforeseen outcome. The first results from the broad spectrum of activity of antitrypsin Pittsburgh. As well as inhibiting thrombin and the contact proteases, the Pittsburgh mutant also inhibits activated protein C. Inhibition of the protein C system is known to exacerbate septic shock. Secondly, a significant quantity of inactive antitrypsin Pittsburgh, cleaved at the reactive centre, was detected in the plasma of the treated animals. Proteolytically altered serpins, including antitrypsin, have been shown to enhance the inflammatory process. Therefore the accumulation of cleaved rAT Pittsburgh might be expected to exacerbate septic shock.

• References

• 1 Anonymous. Increase in national hospital discharge survey cases for septicaemia – United States 1979-87. MMWR Morbidity and mortality weekly report 1990; 39: 31-4.
• 2 Bone RC, Fisher CJ, Clemmer TP. Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17: 389-93.
• 3 Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Inter-leukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest 1985; 76: 2003-11.
• 4 Dinarello CA. Interleukin 1. Rev Infect Dis 1984; 6: 51-95.
• 5 Cerami A, Beutler B. The role of Cachectin/TNF in endotoxin shock and cachexia. Immunol Today 1988; 9: 28-31.
• 6 Nakayasu T, Nagasawa S. Studies on human kininogens. Isolation, characterisation and cleavage by plasma kallikrein or high molecular weight kininogen. J Biochem 1979; 85: 249-58.
• 7 Mason JW, Kleeberg U, Dolan P, Colman RW. Plasma kallikrein and Hageman factor in gram-negative bacteraemia. Ann Intern Med 1970; 73: 545-51.
• 8 Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff C, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN. Treatment of gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-36.
• 9 Greenman RL, Schein RM, Martin MA. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266: 1097-102.
• 10 Fisher CJ, Marra MN, Palardy JE, Marchbanks CR, Scott RW, Opal SM. Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo controlled study. Crit Care Med 1994; 22: 553-8.
• 11 VanDervort AL, Danner RL. Antiendotoxin approaches to septic shock therapy. Crit Care Med 1994; 22: 539-41.
• 12 Smith OP, White W, Vaughan D, Rafferty M, Clafey L, Lyons B, Casey W. Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350: 1590-3.
• 13 Scott CF, Carrell RW, Glaser CB, Kueppers F, Lewis JH, Colman RW. Alpha-1-antitrypsin Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein and factor XII. J Clin Invest 1985; 77: 631-4.
• 14 Hinshaw LB, Bracket DJ, Archer LT, Beller BK, Wilson MF. Detection of the hyper dynamic state of sepsis in the baboon during lethal E. Coli infusion. J Trauma 1983; 23: 361-5.
• 15 Emerson TE, Fournel TE, Leach WJ, Redens TB. Protection against intravascular coagulation and death by antithrombin III in the E. coli endotoxaemic rat. Circulatory Shock 1987; 21: 1-13.
• 16 Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost 1984; 51: 232-5.
• 17 Redens TB, Leach WJ, Bogdanoff DA, Emerson TE. Synergistic protection from lung damage by combining antithrombin III and alpha-1-protease inhibitor in the E. coli endotoxaemic sheep pulmonary dysfunction model. Circulatory Shock 1988; 26: 15-26.
• 18 Taylor FB, Emerson TE, Chang JR, Blick KE. Antithrombin III prevents lethal effects of E. coli infusion in baboons. Circulatory Shock 1988; 26: 227-35.
• 19 Colman RW, Flores DN, De La Cadena RA, Scott CF, Cousens L, Barr PJ, Hoffman IB, Kueppers F, Fisher D, Idell S, Pisarello J. Recombinant α1-antitrypsin Pittsburgh attenuates experimental gram-negative septicaemia. Am J Path 1988; 130: 418-26.
• 20 Heeb MJ, Bischoff R, Courtney M, Griffin JH. Inhibition of activated Protein C by Recombinant a1-antitrypsin variants with Substitution of Argi-nine or Leucine for Methionine 358. J Biol Chem 1990; 265: 2365-9.
• 21 Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by Protein C. Thromb Haemost 1991; 66: 160-5.
• 22 Taylor F, Chang A, Esmon CT, D’Angelo A, D’Angelo SV, Blick KE. Protein C Prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
• 23 Stockley RA, Shaw J, Afford SC, Morrison HM, Burnett D. Effect of alpha-1-Protease Inhibitor on Neutrophil Chemotaxis. Am J Respir Cell Mol Biol 1990; 2: 163-70.
• 24 Banda MJ, Rice AG, Griffin GL, Senior RM. Alpha-1-Protease Inhibitor is a Neutrophil Chemoattractant after Proteolytic Inactivation by Macrophage Elastase. J Biol Chem 1988; 263: 4481-4.
• 25 Corbin LW, Church FC, Hoffman M. Production of chemotactic peptides by neutrophil degradation of heparin cofactor II. Thromb Res 1990; 57: 77-85.
• 26 Kurdowska A, Travis J. Acute Phase Protein Stimulation by α1-Antichymotrypsin-Cathepsin G Complexes. J Biol Chem 1990; 265: 21023-6.